Sign in

You're signed outSign in or to get full access.

Mahendra R. Gupta

About Mahendra R. Gupta

Mahendra R. Gupta (Year of Birth: 1956) is a Non-Interested Director of the Fund since 2018 and has served as Chair of the Audit Committee since 2019; his current term runs to the 2027 annual meeting. He is a Professor at Washington University in St. Louis with over 30 years of academic experience in accounting and management, and oversees seven portfolios in the Fund Complex. He is also a Nominating Committee member. Independence is affirmed via committee composition standards (NYSE American) for Audit and Nominating.

Past Roles

OrganizationRoleTenureCommittees/Impact
Washington University in St. LouisProfessor1990–present Academic expertise in accounting and management
R.J. Mithaiwala (Food manufacturing & retail, India)Partner1977–present N/A
F.F.B. Corporation (Agriculture, India)Partner1977–present N/A
RPMG Research Corporation (Benchmark research)Partner2001–present N/A

External Roles

OrganizationRoleTenureCommittees/Impact
Caleres Inc. (footwear; public)Director2012–present N/A
Foundation of Barnes Jewish HospitalDirector; Chair of Finance CommitteeDirector: 2018–present; Chair: 2024–present Finance Committee Chair
First Bank (finance)Director2023–present N/A
ENDI Corporation (finance)Director2023–present N/A
Consortium for Graduate Study in Management (non-profit)Director2017–2023 N/A
The Oasis Institute (non-profit)Director2022–present N/A
Koch Development Corporation (real estate development)Director2017–2020 N/A
Guardian Angels of St. Louis (not-for-profit)Director2015–2021 N/A

Board Governance

  • Committee assignments and chair roles: Audit Committee Chair; Nominating Committee Member; Non-Interested Director.
  • Independence and committee composition: All Directors except the Interested Director (John Popp) constitute the Audit Committee and Nominating Committee; both committees are composed of independent directors under NYSE American standards.
  • Meeting frequency and attendance: Audit Committee convened five times in FY 2024; Nominating Committee met four times in FY 2024. In FY 2023, the Board convened 24 times and each Director attended at least 75% of Board and committee meetings.
  • Annual meeting attendance policy: The Fund does not have a formal policy regarding Directors’ attendance at the Annual Meeting of Shareholders.
  • Audit oversight: Audit Committee Charter covers pre-approval of audit and permissible non-audit services; the Committee reviewed FY 2024 audited financials, discussed PCAOB-required matters with EY, and recommended inclusion in the Annual Report. Non-audit fees billed were $0 (EY, 2024) versus $34,500 (PwC, 2023); all services were pre-approved.

Fixed Compensation

MetricFY 2023FY 2024
Aggregate Compensation From the Fund (USD)$38,725 $42,508
Total Compensation From Fund + Fund Complex (USD)$208,375 $195,005
Director Annual Fee (USD)$23,100 N/A (cash fees disclosed in aggregate)
Per Board Meeting Fee (USD)$2,100 per meeting N/A (cash fees disclosed in aggregate)
Audit Committee Chair Annual Fee (USD)$2,100 $2,608.50 (effective Jan 1, 2024)
Nominating Committee Chair Annual Fee (USD)$2,000 (not applicable to Gupta; he is a member) $1,071.50 (not applicable to Gupta)
Board Chair Annual Fee (USD)$5,250 (not applicable to Gupta) $4,764 (not applicable to Gupta)
One-time Complex Fee (USD)$25,000 for 2023 UBS-CS merger-related meetings (Fund Complex) N/A

Notes:

  • The Fund has no bonus, profit sharing, pension or retirement plans; officers or Directors who are also officers/directors of UBS AM (Americas) receive no compensation from the Fund.
  • 7 funds comprise the Fund Complex in 2024 (changed from 9 in 2023); Directors serve on each board in the complex.

Performance Compensation

ComponentStatusDetail
Annual/Target BonusNone disclosedThe Fund has no bonus, profit sharing, pension or retirement plans.
Equity Awards (RSUs/PSUs)Not disclosedProxy tables report cash fees; no stock awards presented.
Option AwardsNot disclosedNo option awards presented in compensation tables.
Performance Metrics (e.g., revenue, EBITDA, TSR, ESG)Not applicableDirector compensation is cash-based fees; no performance-tied components disclosed.
Clawback / CoC / SeveranceNot disclosedNo director-specific clawbacks, severance, or CoC terms disclosed.

Other Directorships & Interlocks

CompanyPublic/PrivateRolePotential Interlock/Exposure
Caleres Inc.PublicDirectorConsumer retail exposure; no Fund-related transactions disclosed.
First Bank; ENDI CorporationFinanceDirectorFinancial services exposure; no Fund-related transactions disclosed.
Foundation of Barnes Jewish HospitalNon-profitDirector; Finance Committee ChairHealthcare ecosystem; governance role; no Fund-related transactions disclosed.
Others (Oasis Institute; Consortium; Koch Development; Guardian Angels)Non-profit/PrivateDirectorCommunity/real estate exposure; no Fund-related transactions disclosed.

As of Feb 28, 2025, none of the Non-Interested Directors or their immediate family members owned any class of securities in Credit Suisse or entities controlling/controlled by Credit Suisse (other than registered investment companies), mitigating adviser-related conflicts.

Expertise & Qualifications

  • Over 30 years as an accounting and management academic; Professor at Washington University in St. Louis.
  • Longstanding governance roles across finance, healthcare, and consumer sectors; Finance Committee chair experience.
  • Serves as Audit Committee Chair since 2019; Nominating Committee Member; oversees seven portfolios in the Fund Complex.

Equity Ownership

CategoryAs of Feb 29, 2024As of Feb 28, 2025
Dollar Range of Equity Securities in the FundA. None A. None
Aggregate Dollar Range Across Credit Suisse Family of Investment CompaniesE. Over $100,000 E. Over $100,000
Aggregate ownership by Fund Directors/Officers (Fund level)Less than 1% of outstanding shares (aggregate) Less than 1% of outstanding shares (aggregate)

Footnotes:

  • Beneficial ownership determined under Rule 16a-1(a)(2) of the Exchange Act.
  • The “Credit Suisse Family of Investment Companies” comprises registered investment companies sharing the adviser and holding themselves out as related.

Governance Assessment

  • Strengths: Independent status and leadership in audit oversight (Audit Chair since 2019); committees composed solely of independent Directors; active committee cadence (5 Audit; 4 Nominating in FY 2024); robust board activity in FY 2023 (24 meetings) with each Director attending at least 75%; Audit Committee documented oversight of auditor independence and pre-approval of services; timely Section 16 filings.
  • Alignment and engagement: Compensation is fee-based cash (retainer, meeting, chair fees) with no performance linkage; FY 2024 aggregate compensation from Fund $42,508 and $195,005 from Fund + Complex, consistent with multi-fund governance workload.
  • Watch items:
    • RED FLAG: No direct share ownership in the Fund (Dollar Range A: None), which can signal lower direct alignment for CIK-specific outcomes, though fund directors are not required to hold shares.
    • Multiple external commitments across public, private, and non-profit boards imply significant time demands; however, proxy attendance thresholds were met in FY 2023, and committee meetings remained active in FY 2024.
  • Structural notes: The Fund does not have a Compensation Committee; director fees and committee structures are overseen by the Board with disclosed fee schedules and adjustments effective Jan 1, 2024.

Overall signal: Gupta’s independence, long-standing audit leadership, and documented committee activity support board effectiveness; the lack of Fund share ownership is a modest alignment concern typical in the registered fund space.